Skip to main content

Research

Hawiger still blazing a trail in inflammation research

Nov. 10, 2022—Vanderbilt research describes a new investigational peptide drug that can penetrate immune and nonimmune cells, and block inflammatory signaling in a preclinical model of atopic dermatitis — eczema.

Read more


Clinical trial at VUMC tests novel treatment for asthma

Nov. 10, 2022—VUMC has begun enrolling patients with asthma in a clinical trial of a novel treatment: a medication approved to treat diabetes and obesity.

Read more


Alzheimer’s risk factor and cognition

Nov. 8, 2022—Vanderbilt researchers found that a protein with roles in innate immunity worsens memory at baseline in carriers of APOE-e4, the strongest genetic risk factor for Alzheimer’s disease, further implicating neuroinflammation in cognitive decline.

Read more


Gene mutations impair gut barrier

Nov. 7, 2022—Mutations in a cell membrane transporter protein impair the integrity of the gut lining, contributing to chronic gastrointestinal distress for people with the mutations, Vanderbilt researchers report.

Read more


Study finds Moderna’s COVID-19 vaccine safe and effective for young children

Nov. 4, 2022—A Vanderbilt study finds that Moderna’s COVID-19 vaccine is safe and effective in children 6 months to 5 years of age.

Read more


C. diff infections drop in children

Nov. 3, 2022—The number of pediatric infections caused by Clostridioides difficile (C. diff) decreased from 2013 to 2019, likely due to an increase in antibiotic stewardship programs and improved hospital contact protocols, Vanderbilt researchers found.

Read more


Social behavior brain circuitry

Nov. 3, 2022—Vanderbilt researchers have identified a novel mechanism regulating social behavior: Neuropeptide Y signaling in the nucleus accumbens brain region.

Read more


Study explores possible drug target for neurological problems

Nov. 3, 2022—A team at Case Western Reserve University and Vanderbilt University Medical Center has determined with atomic-level precision how two established drugs bind to and alter the conformation of a cell membrane transporter protein called NKCC1, shutting down its activity.

Read more


New VUSM master’s program offers broad training in biomedical imaging

Nov. 3, 2022—A new Master of Imaging Science program at Vanderbilt will immerse students in the full spectrum of biomedical imaging and provide hands-on clinical and research experience.

Read more


Event to spotlight VUMC’s COVID-19 research efforts

Nov. 3, 2022—The public is invited to listen in as scientists on the forefront of COVID-19 research at Vanderbilt University Medical Center share their personal stories on Wednesday afternoon, Nov. 16, in 214 Light Hall.

Read more


VUMC mourns loss of noted hypertension expert Elijovich

Oct. 28, 2022—Fernando Elijovich, MD, professor of Medicine in the Division of Clinical Pharmacology at Vanderbilt University Medical Center, died in Nashville on Oct. 21. He was 77.

Read more


Translational Research Forum highlights range of studies

Oct. 27, 2022—The 2022 Vanderbilt Translational Research Forum exemplified the range of studies conducted at Vanderbilt University Medical Center that are translating scientific discovery into clinical practice.

Read more


Recent Stories from VUMC News and Communications Publications

Vanderbilt Medicine
Hope
Momentum
VUMC Voice

more